EMP1(EMP1) - 药物靶点：EPO receptor_在研适应症：贫血_专利_临床

概要

基本信息

药物类型

合成多肽

别名-

靶点

EPO receptor

作用机制

EPO receptor激动剂(促红细胞生成素受体激动剂)

治疗领域

血液及淋巴系统疾病

在研适应症

贫血

非在研适应症-

原研机构

在研机构

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

序列信息

Sequence Code 8829

关联

100 项与 EMP1 相关的临床结果

登录后查看更多信息

100 项与 EMP1 相关的转化医学

登录后查看更多信息

100 项与 EMP1 相关的专利（医药）

登录后查看更多信息

1

项与 EMP1 相关的文献（医药）

2009-06-01·Peptides3区 · 医学

Restrain of bone growth by Estrogen-Mimetic Peptide-1 (EMP-1): A micro-computed tomographic study

3区 · 医学

Article

作者: Alon Bajayo ; Roni Kasher ; Ephraim Katchalski-Katzir ; Itai Bab ; Nava Nevo ; Mati Fridkin ; Fortune Kohen ; Yankel Gabet

Estrogen has a key role in the regulation of skeletal growth and maintenance of bone mass. Recently, we developed peptides having estrogen-like activity as potential estrogen-based new drugs. The aim of the present study was to evaluate the influence of long-term administration of the most efficacious of these peptides, the hexapeptide EMP-1 (VSWFFE), on bone mass and development. EMP-1 was injected daily to ovariectomized (OVX) and intact young, sexually mature female mice for 10 weeks. Whole femora, including the cartilaginous growth plates were analyzed by micro-computed tomography (microCT). We found that peptide EMP-1 restrains bone growth in OVX mice: it inhibited dramatically bone longitudinal growth (40%), and decreased femoral diaphyseal diameter. Peptide EMP-1 had no effect on bone growth in normal mice, and did not influence the OVX-induced bone loss. We then developed a new microCT methodology to evaluate uncalcified and calcified growth plate parameters. In the OVX mice, peptide EMP-1 reduced volume and thickness of the uncalcified growth plate, a possible cause for the inhibition of bone longitudinal growth. Peptide EMP-1 may be used as a lead compound for the development of drugs to treat acromegalic patients.

100 项与 EMP1 相关的药物交易

登录后查看更多信息